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Background: A regular evaluation of therapeutic efficacy in sentinel sites and a system of surveillance are required
to establish treatment guidelines and adapt national anti-malarial drug policy to the rapidly changing epidemiology
of drug-resistant malaria. The current anti-malarial treatment guideline in Mauritania, officially recommended since
2006, is based on artemisinin-based combination therapy. The aim of the present study was to evaluate clinical
efficacy and tolerance of artesunate-amodiaquine, the first-line treatment for acute uncomplicated malaria, in
Mauritanian paediatric and adult patients to validate its continued use in the country.
Methods: Plasmodium falciparum-infected symptomatic patients aged > six months were enrolled in Kobeni and
Timbedra in southern Mauritania in September to October 2013. Co-formulated artesunate-amodiaquine was
administered at the recommended dose over three days. Patients were followed until day 28. Parasitological and
clinical response was classified according to the standard 2009 World Health Organization protocol.
Results: A total of 130 patients (65 in Kobeni and 65 in Timbedra) were enrolled in the study. Seventeen patients
(13.1%) were either excluded (before PCR correction) or lost to follow-up. Based on the per protocol analysis,
artesunate-amodiaquine efficacy (i.e., the proportion of adequate clinical and parasitological response) was 96.6% in
Kobeni and 98.2% in Timbedra before PCR correction. Late clinical failure was observed in two patients in Kobeni
and one patient in Timbedra. After PCR correction, the efficacy rate in the two study sites was 98.2%. On day 3, all
patients were afebrile and had negative smears. Treatment was well tolerated.
Conclusions: Artesunate-amodiaquine is well tolerated and highly efficacious for the treatment of uncomplicated
P. falciparum malaria. In the majority of patients, fever and parasitaemia were rapidly cleared before day 3. The
results support the national anti-malarial drug guideline for a continued use of artesunate-amodiaquine as a
first-line drug for uncomplicated malaria in southern Mauritania.
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Figure 1 Study sites in Mauritania.
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Malaria is one of the major public health problems in
Mauritania. Every year, between 200,000 and 300,000 ma-
laria cases are officially notified, mostly without laboratory
confirmation of clinical diagnosis [1]. Most Plasmodium
falciparum infections occur in the sahelian south of the
country, where transmission is seasonal (generally July to
October or November), and malaria represents the first
cause of outpatient consultation (25%), hospitalization
(35.5%) and mortality (39%).
Resistance to chloroquine and sulphadoxine-pyrime-
thamine is widespread in West Africa [2]. Since about a
decade ago, many West African countries have initiated
the evaluation of therapeutic efficacy of artemisinin-based
combination therapy (ACT), in particular artesunate-
amodiaquine (ASAQ) and artemether-lumefantrine, for
the treatment of acute uncomplicated falciparum malaria,
and have adopted new treatment guidelines based on the
systematic use of ACT [2].
In Mauritania, clinical data on anti-malarial drug efficacy
are scarce. In one of the first published papers on a re-
gional survey of clinical resistance to chloroquine between
1987 and 1990 in francophone West Africa, it was re-
ported that Mauritania was still free of chloroquine resis-
tance [3]. However, in a clinical study performed in 1994
in Kiffa, southern Mauritania, using the seven-day test,
three of 31 (9.7%) patients still had positive smears and
one remained febrile on day 7 [4]. In 1997, indirect evi-
dence for chloroquine resistance in vitro was reported in
thre of five P. falciparum isolates obtained from travellers
returning from Mauritania to France [5]. Chloroquine-
resistant P. falciparum was confirmed in another clinical
study conducted in 1998 in Aioun and Kobeni (southern
Mauritania) in which it was reported that 33 of 85 (38.8%)
patients treated with chloroquine and followed for 14 days
failed to respond to the treatment [6]. The high prevalence
of mutant P. falciparum chloroquine resistance trans-
porter (pfcrt) found in that study supports clinical resis-
tance to chloroquine in southern Mauritania. By contrast,
analysis of key codons in the molecular markers for
sulphadoxine-pyrimethamine resistance (dihydropteroate
synthase (dhps) and dihydrofolate reductase (dhfr), re-
spectively) in the same samples suggested low prevalence
(<22%) of antifolate resistance [7].
Since 2006, in line with the anti-malarial drug policies
in neighbouring countries, notably Senegal and Mali,
Mauritanian Ministry of Health recommends the syste-
matic use of ASAQ and artemether-lumefantrine for the
first- and second-line treatment of acute uncomplicated
malaria, respectively. This new treatment guideline is not
based on data obtained in the country as ACT has never
been evaluated before in Mauritanian patients using a
standardized protocol. The present single-arm study was
performed to evaluate the efficacy and tolerance of ASAQin P. falciparum-infected, symptomatic paediatric and
adult patients in southern Mauritania where P. falciparum
is known to be endemic.
Methods
Study sites
The clinical studies were conducted in two study areas in
southern Mauritania: Kobeni (Hodh El Gharbi province)
and Timbedra (Hodh Echargui province) (Figure 1). The
town of Kobeni (15°49′02″ north, 09°24′39″ west) is situa-
ted about 105 km south of the city of Aioun (regional capi-
tal of Hodh El Gharbi, 980 km southeast of Nouakchott)
along Aioun-Nioro route and lies about 20 km from the
border with Mali. According to the Mauritanian Office
Nationale de la Statistique, there were 97,239 inhabitants
in the department (locally referred to as moughataa) of
Kobeni in 2013. Only one health centre attends to the
health needs of the population residing in Kobeni.
The city of Timbedra (15°49′02″ north, 09°24′39″ west)
is situated in the southeastern region of the country (Hodh
Ech Chargui region) and lies along the major road, la route
de l’Espoir, about 1,100 km from Nouakchott. There were
76,932 inhabitants in the department (moughataa) of
Timbedra in 2013. The agricultural and pastoral lifestyle
in these two cities is similar. During the rainy season (July
to October or November), an average of 30 febrile cases
per day are treated in the health centres in Kobeni and
Timbedra.
Patients
Patients spontaneously consulting at the health centres
in September and October 2013 were enrolled after
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met: age > six months old (without upper limit), P. fal-
ciparum mono-infection with parasitaemia between 250
and 100,000 asexual parasites/μL, presence of fever (axil-
lary temperature ≥37.5°C) or history of fever 24 hours
preceding medical consultation, and ability to swallow
oral medication [8]. Patients with danger signs or signs
of severe and complicated malaria, as defined by the
World Health Organization (WHO) [9], mixed Plas-
modium species, severe malnutrition, fever due to con-
comitant diseases, and history of allergic reaction to
amodiaquine or artemisinin derivatives were excluded.
Due to the relative contra-indication of artemisinin
derivatives during the first trimester of pregnancy and
during breastfeeding, married women with a positive
pregnancy test and breastfeeding women were excluded
from the present study. In addition, due to the ethical
problem in performing pregnancy test in adolescent girls
aged between 12 and 18 years old and single adult
women >18 years old, these two categories of patients
were excluded from the study protocol.
Laboratory examinations, treatment and follow-up
Finger-prick capillary blood was collected to prepare and
examine Giemsa-stained thin and thick smears under the
microscope, according to standard WHO procedures [10].
Blood samples were imbibed onto Whatman 3MM filter
paper (GE Healthcare Life Sciences, Bucks, UK) and dried
to store parasite DNA. Haemoglobin levels were mea-
sured using HemoCue® Hb 301 system (HemoCue AB,
Angelholm, Sweden).
ASAQ (batch no. 1084 for paediatric tablet containing
25 mg artesunate + 67.5 mg amodiaquine base; batch no.
5433 for adult tablet containing 100 mg artesunate +
270 mg amodiaquine base; Sanofi-Aventis, Antony, France)
was administered on days 0, 1 and 2 at the doses recom-
mended by the manufacturer on mg base per weight basis.
Each dose administration was supervised by one of the
team members, and patients were observed for at least
30 minutes after drug intake for possible vomiting or ad-
verse effects. In case of vomiting during the observation
period, the same dose was given, and the patient was ob-
served for an additional 30 minutes. In case of repeated
vomiting, the patient was withdrawn from the study proto-
col and rescue treatment was administered (parenteral
quinine, 8 mg base/kg body weight three times a day for
seven days or quinine followed by ASAQ or artemether-
lumefantrine as soon as the patient tolerated oral me-
dication). Paracetamol (10 mg/kg body weight) was ad-
ministered to all patients three times a day for fever and
headache.
Patients were followed on days 1, 2, 3, 7, 14, 21, and
28 [8]. Finger-prick capillary blood was collected for
blood examination from day 2 to day 28 and imbibedonto Whatman 3MM filter paper from day 7 to 28, inclu-
ding any unscheduled visit due to an occurrence of fever,
clinical aggravation, or treatment failure. Patients who
failed to respond to ASAQ treatment were treated with
artemether-lumefantrine (20 mg of artemether + 120 mg of
lumefantrine per tablet; one to four tablets per dose, twice
a day for three days, according to the manufacturer’s in-
structions), as recommended by the national guideline for
anti-malarial treatment. In Kobeni, haemoglobin measure-
ment was performed on day 0 and repeated on day 28.
Study endpoints
The primary endpoint was determined on day 28 and clas-
sified into one of the following categories: early treatment
failure (ETF), late clinical failure (LCF), late parasitological
failure (LPF), or adequate clinical and parasitological re-
sponse (ACPR), as defined by the WHO [8]. Treatment
failure refers to one of the following outcomes: ETF, LCF or
LPF. ACPR is synonymous with treatment success. The
secondary endpoints included the proportion of afebrile pa-
tients with negative smears on day 3, and for the study con-
ducted in Kobeni, haemoglobin improvement on day 28.
PCR and genotyping
Parasite DNA was extracted from filter papers using the
Chelex method [11]. Plasmodium species was determined
using 18S rRNA as the target molecule [12]. Genotypes of
paired pre-treatment and recurrent parasites on or after
day 7 were determined to distinguish between recrudes-
cence (i.e., re-appearance of the same parasite population
as that of pretreatment sample) and re-infection (i.e.,
appearance of different parasite populations). Genotyping
was based on three polymorphic markers, merozoite
surface antigen-1 (msa1), merozoite surface antigen-2
(msa2), and glutamine-rich protein (glurp), as recom-
mended by the WHO [13].
Statistical analysis
The sample size of 50 patients (plus 20% to anticipate
losses due to exclusions, withdrawals and lost-to-follow-
up), i.e., a minimum of 60 patients, was calculated on
the basis of an expected failure rate of 5% extrapolated
from data obtained in Senegal, 10% precision and a con-
fidence level of 95% [8].
Haemoglobin values on day 0 and day 28 were com-
pared using the paired t-test. Proportions were arranged
in a 2 × 2 contingency table and compared using Fisher’s
exact test. All statistical tests were two-sided, and the
level of statistical significance was fixed at P <0.05. Sig-
maStat 3.5 (Systat Software, Inc, Point Richmond, CA,
USA) software was used for these analyses.
As recommended in the WHO protocol [8], per proto-
col analysis of the percentage of ACPR and Kaplan-
Meier survival analysis were performed to calculate the
Table 2 Per protocol analysis of clinical outcome of
artesunate-amodiaquine treatment in southern
Mauritania
Outcome Kobeni Timbedra
Number of enrolled patients 65 65
Exclusion after enrollment
(before PCR correction), n
7 2
Lost-to-follow-up, n 0 8
Per protocol population 58 55
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28-day follow-up period. Data were entered into the
standard pre-programmed Excel worksheet provided by
the Global Malaria Programme, WHO, for per protocol
analysis. Survival curves were plotted and analysed using
Prism 4.0 (GraphPad Software, Inc, La Jolla, CA, USA)
software. Quantitative variables were compared between
the patient population in Kobeni and Timbedra using
the unpaired t-test. The significance level was fixed at
P <0.05.
Ethical approval
The study was reviewed and approved by an ad hoc
Mauritanian national ethics committee and the ethics
committee of the WHO (Geneva, Switzerland). The pur-
pose of the study was explained to the patients (and
their parents or legal guardians for children and adoles-
cents) in local dialect. Informed written consent was ob-
tained from adult patients or caretakers of paediatric
patients aged under 12 years. For adolescents aged bet-
ween 12 and 18 years old, an informed written consent
was obtained from both the patients themselves and
their parents or legal guardians.
Results
A total of 130 patients (65 patients in each study site) were
enrolled in the study (Table 1). There was no significant dif-
ference (P >0.05) in the mean age and body weight of the
two patient populations in Kobeni and Timbedra. However,
the mean body temperature and parasitaemia wereTable 1 Patient characteristics on inclusion in two study





Mean age (±SD, range), yr 10.5 ± 5.7 (2–30) 11.9 ± 11.2 (1–65)
Age groups
Under 5 years old, n (%) 7 (10.8) 11 (16.9)
5-18 years old, n (%) 51 (78.5) 48 (73.8)
>18 years old, n (%) 7 (10.8) 6 (9.2)
Sex ratio (M/F) 1.3 (37/28) 1.5 (39/26)
Mean weight
(±SD, range), kg
29.4 ± 15.0 (8–70) 29.0 ± 17.9 (7–0)
Mean body temperature
(±SD, range), °C
38.6 ± 1.0 (36.6-40.6)* 37.6 ± 1.3 (36.0-40.6)
Proportion of patients






9,230 (7,050-12,100)* 2,090 (1,660-2,630)
1,860-100,400 312–22,600
*Asterisks denote a statistically significant difference (P <0.05) in the mean
values between the patient populations in Kobeni and Timbedra.significantly higher (P <0.05) in Kobeni than in Timbedra.
This observation was probably related to the fact that the
majority of patients seen in Kobeni health centre (53 of 65
patients, 81.5%) were febrile at the time of consultation,
whereas in Timbedra most patients (30 of 65 patients,
46.1%) presented with a recent history of fever but were
afebrile at the time of consultation and enrollment.
Of 130 enrolled patients, nine (6.9%) were excluded
after inclusion for protocol violation (n = 3), repeated
vomiting (n = 3), mixed P. falciparum-Plasmodium vivax
infection (n = 1), or withdrawal of consent (n = 2), and
eight (6.2%) were lost to follow-up (Table 2). The per
protocol population before PCR correction consisted of
58 and 55 patients in Kobeni and Timbedra, respectively.
In Kobeni, per protocol analysis showed ASAQ efficacy
of 96.6% before PCR correction. There were two cases of
LCF, one occurring on day 5 and the other on day 27. The
patient responding with LCF on day 5 (i.e., recrudescence)
was a 20-month-old boy presenting with a high-grade fever(before PCR correction), n
PCR-uncorrected outcome
Early treatment failure, n (%) 0 0
Late clinical failure (LCF), n (%) 2 (3.4) 1 (1.8)
Late parasitological failure, n (%) 0 0
Adequate clinical and
parasitological response, n (%)
56 (96.6) 54 (98.2)




Early treatment failure, n (%) 0 0
Late clinical failure (LCF) due to
recrudescence, n (%)
1 (1.8) 1 (1.8)
Late parasitological failure, n (%) 0 0
Adequate clinical and parasitological
response, n (%)
56 (98.2) 54 (98.2)
Patients with fever on day 1, n (%) 13 (22.4) 7 (12.7)
Patients with fever on day 2, n (%) 2 (3.4) 0
Patients with fever on day 3, n (%) 0 0
Patients with parasitaemia on day 2, n (%) 46 (79.3) 25 (45.5)
Patients with parasitaemia on day 3, n (%) 0 0
*In Kobeni, one patient was excluded (i.e., censored) after PCR correction due
to re-infection.
Figure 3 Survival curves after artesunate-amodiaquine treatment
(PCR-corrected) in Kobeni (black squares) and Timbédra
(black circles).
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haemoglobin of 7.8 g/dL on day 0. He was afebrile from
day 1 to day 3 and had a positive smear on day 2 (4,600
asexual parasites/μL) and a negative smear on day 3, but
was seen on day 5 with a high-grade fever of 39.6°C and a
positive smear (880 asexual parasites/μL). There were no
signs and symptoms of clinical aggravation. The patient
was treated with artemether-lumefantrine. The other pa-
tient responding with LCF was an eight-year-old boy
presenting with a high-grade fever of 40.2°C and 17,140
asexual parasites/μL on day 0. He initially responded well
to ASAQ treatment. He was afebrile from day 1 to day 21
and had a parasitaemia of 460 asexual parasites/μL on day
2 and negative smears from day 3 to day 21. On day 27,
the patient was febrile (37.6°C) and had a positive smear
(13,620 asexual parasites/μL). PCR analysis showed that
the recurrence of fever and positive smear on day 27 was
due to re-infection. After PCR adjustment, ASAQ efficacy
was 98.2% in Kobeni.
In Timbedra, the PCR-unadjusted outcome also showed
high efficacy (98.2% ACPR) in the per protocol popula-
tion, with only one LCF occurring on day 21 in a seven-
year-old boy. This patient presented with fever (38.2°C)
and 1,782 asexual parasites/μL on day 0. He was afebrile
from day 1 to day 14 and aparasitaemic from day 2 to
day 14. On day 21, the patient was seen with a low-grade
fever (37.7°C) and 432 asexual parasites/μL. PCR analysis
showed recrudescence.
The overall efficacy of ASAQ was 98.2% after PCR cor-
rection (56 of 57 patients with ACPR (one patient was
censored due to re-infection) in Kobeni and 54 of 55 pa-
tients with ACPR in Timbedra) (Figures 2 and 3). In both
study sites, there was no case of LPF or ETF. ASAQ
cleared fever and parasitaemia rapidly in Mauritanian pa-
tients (Table 2). Per protocol analysis showed that 13 and
seven patients were still febrile on day 1 and 2 and noFigure 2 Survival curves after artesunate-amodiaquine treatment
(PCR-uncorrected) in Kobeni (black squares) and Timbédra
(black circles).patients were febrile on day 2 in Kobeni and Timbedra,
respectively. None of the patients was febrile or parasitae-
mic on day 3.
ASAQ was well-tolerated. Thirty-three of 130 patients
(25.4%) reported the following mild and transient adverse
effects (n, %): nausea or vomiting (19, 14.6%), headache
(9, 6.9%), dizziness (1, 0.8%), anorexia (1, 0.8%), pruritus
(2, 1.5%; one patient reported pruritus on day 1 and sec-
ond patient on day 3), and palpitation (1, 0.8%). Three pa-
tients with LCF (two in Kobeni and one in Timbedra) did
not report vomiting or any other adverse effects. Although
it is difficult to distinguish between malaria-associated
symptoms and drug-induced adverse effects, the adverse
events reported by the patients resolved spontaneously
within 24 hours following administration of the first treat-
ment dose. Pruritus that occurred on day 3 in one patient
disappeared on day 4 without any specific treatment. No
serious adverse effect was observed.
Paired haemoglobin values were available from all 56
patients followed until day 28 in Kobeni. There was a sta-
tistically significant (P <0.05) increase in the mean (± SD)
haemoglobin value from 9.94 ± 1.66 g/dl on day 0 to the
mean (± SD) haemoglobin value of 11.2 ± 1.5 g/dl on day
28. The improvement in haemoglobin values is another
benefit of a rapid and effective anti-malarial treatment for
patients, in particular in young African children who tend
to suffer from malaria-associated anaemia more than
adults.
Conclusions
The rapid and high efficacy of ASAQ observed in the
present study is comparable to that found in the neigh-
bouring countries, Senegal and Mali [14-16]. The results
of the first clinical evaluation of ASAQ efficacy in
Mauritania also showed that this ACT is well tolerated by
malaria-infected Mauritanian children and adults. Fever
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majority of patients. Treatment was associated with an
improvement in haemoglobin values on day 28. These
clinical data support the current treatment guideline that
recommends the use of ASAQ for the first-line treatment
of acute uncomplicated falciparum malaria in southern
Mauritania.
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